

Third-line regimens

Recommendations

1. It is recommended that National programs should develop policies for third-line therapy that address funding, sustainability and the provision of equitable access to ART. (Conditional recommendation, low quality of evidence)
2. Third line regimens should include ideally two new drugs with predicted activity such as boosted DRV, raltegravir and etravirine. (Conditional recommendation, low quality of evidence)
3. If patients are on a failing regimen without further therapeutic options, a tolerated regimen should be continued. (Conditional recommendation, very low quality of evidence)